U
IRD

UBS’s Opus Genetics IRD Stock Holding History

UBS’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-40
Closed -$17K – 10829
2014
Q2 		$17K Sell
40
-693
-95% -$315K ﹤0.01% 8286
2014
Q1 		$381K Buy
733
+694
+1,779% +$375K ﹤0.01% 4528
2013
Q4 		$10K Buy
39
+37
+1,850% +$7.81K ﹤0.01% 9001
2013
Q3 		$0 Sell
2
-26
-93% -$6.07K ﹤0.01% 10765
2013
Q2 		$6K Buy
+28
New +$4.81K ﹤0.01% 9142

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

UBS's IRD Position: Q3 2014 in Review

UBS sold out of Opus Genetics (IRD) in Q3 2014, closing a stake of 40 shares — an estimated $17K sold.

UBS first reported a position in IRD in Q2 2013 and held it in 5 quarters. The position peaked at $381K in Q1 2014. 31 funds tracked by Wall St. Rank hold IRD as of Q3 2014.

  • UBS reported no remaining Opus Genetics position as of Q3 2014 after selling out during the quarter.
  • UBS sold 40 Opus Genetics shares in Q3 2014, an estimated $17K.
  • UBS first reported a position in Opus Genetics in Q2 2013 and held it in 5 quarters.
  • UBS's Opus Genetics position peaked at $381K in Q1 2014.
  • 31 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.